Direct acting oral anticoagulants versus low molecular weight heparin for primary thromboprophylaxis in cancer patients
Introduction Low molecular weight heparin is currently the standard therapy for the primary prevention of thromboembolic disease in cancer patients. The use of direct-acting anticoagulants could be an alternative, but its efficacy and safety profile in these types of patients remains unclear. Me...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medwave Estudios Limitada
2021-05-01
|
| Series: | Medwave |
| Subjects: | |
| Online Access: | https://www.medwave.cl/link.cgi/Medwave/PuestaDia/ResEpis/8178.act |